Evaluación del incumplimiento en la práctica clínica

[How to assess and to improve adherence in clinical practice?]

Prevalence of non-adherence of pharmacological therapy in hypertension is between 35 and 50%. In every uncontrolled hypertensive one should assess drug adherence as the cause. Several validated methods to detect noncompliance exist, being most frequently used Haynes test, pill count, and use of electronic prescription. Strategies to improve compliance should include a combination of adequate information to patients, a simplified scheme of treatment, and periodic adherence assessment. Programs for home self-measurement of blood pressure, use of double or triple drug fixed combinations, group health education, reminders, calendars, and cards enforcement, and improving doctor-patient relationship are also useful tools for compliance optimization.

[Unity is strength: nutritional therapy and physical exercise, an essential relationship]

Introduction

Nutrition therapy and exercise form an essential tandem to maintain the functional capacity of patients and, therefore, improve your quality of life. Oral nutritional supplements are part of the medical nutrition treatment. The success of taking nutritional supplements, lies in the therapeutic adherence. The therapeutic adherence is defined by who as "the degree to which the behavior of a patient, in relation to the taking of medication, monitoring a diet or modifying life habits correspond to the recommendations agreed with the health professional ". There are some factors that limit its achievement. Therefore, we must identify them and have tools to solve them so that the patient does not interrupt the prescribed treatment, both from prevention and intervention.

Therapeutic compliance with rivaroxaban in preventing stroke in patients with non-valvular atrial fibrillation: CUMRIVAFA study

OBJECTIVE

To assess compliance with treatment with rivaroxaban in patients with non-valvular atrial fibrillation.

METHODS

Prospective, longitudinal, multicenter study, developed in 160 Spanish primary or specialized care centers. We included 412 patients treated with rivaroxaban, prescribed for stroke prevention. Three visits were conducted: baseline, 6 and 12 months. Compliance was measured by using electronic monitors (MEMSs) that use a digital record in the form of a microchip in the lid of the drug container that automatically controls its opening and registers the time and date of the opening. We calculated the average compliance percentage (CP), global and daily compliance. We considered compliance to be when CP was 80-100%.

RESULTS

Three hundred and seventy patients ended the study (mean age 75.19, SD: 7.5 years). Global compliance was 84.1% (CI = 79.21-88.99%) and 80.3% (CI = 74.98-85.62%) after 6 and 12 months respectively. Daily compliance was 83.5% (CI = 78.53-88.57%) and 80% (CI = 74.65-85.35%) at 6 and 12 months. Significant differences in the CP between 6 and 12 months were observed. Global CP was 90.77% after 6 months and 89.65% at the end of the study. Daily CP was 90.14% and 87.66% at 6 and 12 months. There were significant CP differences between 6 and 12 months. Non-compliance was associated with a higher number of concomitant diseases, number of drugs taken and weight.

CONCLUSIONS

The percentage of compliance with rivaroxaban was high. A profile of variables that need to be modified in current medical practice, associated with non-compliance, was detected.

[Adherence of Type 2 Diabetes Mellitus approach: Current situation and possible solutions]

Objetivos

Definir el impacto y las causas de la falta de adherencia terapéutica en los pacientes con diabetes mellitus tipo 2 (DM2), las posibles intervenciones para mejorarla y el papel de las distintas partes implicadas.

Diseño

Valoración de cuestionario estructurado mediante método Delphi aplicado en 2 rondas.

Emplazamiento

Estudio realizado en el ámbito de atención primaria.

Participantes

Panel formado por profesionales médicos de reconocido prestigio y con amplia experiencia en diabetes.

Mediciones principales

Valoración a través de una escala Likert de 9 puntos del grado de acuerdo o desacuerdo de 131 ítems agrupados en 4 bloques: impacto; causas de incumplimiento; diagnóstico de la falta de adherencia y de sus posibles causas, y mejores intervenciones y papel de los distintos roles implicados en la mejora de la adherencia.

Resultados

Con una tasa de participación del 76,31%, los profesionales sanitarios de atención primaria consensuaron 110 de las 131 aseveraciones propuestas (84%), mostrando acuerdo en 102 ítems (77,9%) y desacuerdo en 8 (6,1%). No se logró consenso en 21 ítems.

Conclusiones

La falta de adherencia en los pacientes con DM2 dificulta lograr el control terapéutico. La formación específica y disponer de los recursos necesarios en la consulta son esenciales para minimizar el impacto de la falta de adherencia terapéutica.